Literature DB >> 32815389

A concern about survival time as an endpoint in coronavirus disease 2019 clinical trials.

Kay See Tan1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32815389      PMCID： PMC7530002          DOI： 10.1177/1740774520946026

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  9 in total

1.  Polymyxin B hemoperfusion and mortality in abdominal septic shock.

Authors:  Andre C K B Amaral
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

2.  Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial.

Authors:  S Nava; N Ambrosino; E Clini; M Prato; G Orlando; M Vitacca; P Brigada; C Fracchia; F Rubini
Journal:  Ann Intern Med       Date:  1998-05-01       Impact factor: 25.391

3.  Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.

Authors:  Dinna N Cruz; Massimo Antonelli; Roberto Fumagalli; Francesca Foltran; Nicola Brienza; Abele Donati; Vincenzo Malcangi; Flavia Petrini; Giada Volta; Franco M Bobbio Pallavicini; Federica Rottoli; Francesco Giunta; Claudio Ronco
Journal:  JAMA       Date:  2009-06-17       Impact factor: 56.272

4.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

5.  Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies.

Authors:  David Schoenfeld
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

6.  Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.

Authors:  Didier M Payen; Joelle Guilhot; Yoann Launey; Anne Claire Lukaszewicz; Mahmoud Kaaki; Benoit Veber; Julien Pottecher; Olivier Joannes-Boyau; Laurent Martin-Lefevre; Matthieu Jabaudon; Olivier Mimoz; Rémi Coudroy; Martine Ferrandière; Eric Kipnis; Carlos Vela; Stéphanie Chevallier; Jihad Mallat; René Robert
Journal:  Intensive Care Med       Date:  2015-04-11       Impact factor: 17.440

7.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

8.  A real-time dashboard of clinical trials for COVID-19.

Authors:  Kristian Thorlund; Louis Dron; Jay Park; Grace Hsu; Jamie I Forrest; Edward J Mills
Journal:  Lancet Digit Health       Date:  2020-04-24

9.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.

Authors:  Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell
Journal:  Lancet       Date:  2020-05-19       Impact factor: 79.321
  9 in total
  1 in total

1.  Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events.

Authors:  Jan Beyersmann; Tim Friede; Claudia Schmoor
Journal:  Biom J       Date:  2021-10-22       Impact factor: 1.715
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.